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the major environmental risk factor for rheumatoid arthritis (RA) is smoking, which according to a 
widely accepted model induces protein citrullination in the lungs, triggering the production of anti-
citrullinated protein antibodies (ACPA) and RA development. Nevertheless, some research findings 
do not fit this model. Therefore, we obtained six independent cohorts with 2253 RA patients for a 
detailed analysis of the association between smoking and RA autoantibodies. our results showed a 
predominant association of smoking with the concurrent presence of the three antibodies: rheumatoid 
factor (RF), ACPA and anti-carbamylated protein antibodies (ACarPA) (3 Ab vs. 0 Ab: OR = 1.99, p = 2.5 
× 10–8). Meta-analysis with previous data (4491 patients) confirmed the predominant association 
with the concurrent presence of the three antibodies (3 Ab vs. 0 Ab: OR = 2.00, p = 4.4 ×10–16) and 
revealed that smoking was exclusively associated with the presence of RF in patients with one or two 
antibodies (Rf+1+2 vs. Rf−0+1+2: oR = 1.32, p = 0.0002). In contrast, no specific association with ACPA 
or AcarpA was found. therefore, these results showed the need to understand how smoking favors the 
concordance of RA specific antibodies and RF triggering, perhaps involving smoking-induced epitope 
spreading and other hypothesized mechanisms.
Rheumatoid arthritis (RA) is a systemic autoimmune disease that can be divided in two pathogenic subgroups1,2. 
The largest subgroup comprises the patients presenting RA specific autoantibodies. These antibodies include the 
rheumatoid factor (RF), which is directed against the Fc of the IgG, and antibodies against some post-translational 
protein modifications. The best characterized are anti-citrullinated protein antibodies (ACPA), which in the 
clinic are assayed as anti-cyclic citrullinated peptides or anti-CCP, and the anti-carbamylated protein antibodies 
(ACarPA), which are not yet analyzed beyond research studies. The antibody positive patients are known as sero-
positive and they represent more than two thirds of the total, while the remaining are the seronegative patients. 
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The seropositive patients have a clear component of genetic susceptibility and a defined disease story and autoim-
mune pathogenesis, which are less clear in the seronegative patients1–5.
Also, smoking, which is the major environmental risk factor for RA, is specific of seropositive RA6,7. In the 
ACPA positive patients, the risk is potentiated by interaction with the HLA-DRB1 shared epitope (SE)8–10. This 
interaction together with protein citrullination in the bronchoalveolar lavage (BAL) cells of smokers has been at 
the basis of an influential pathogenic model11. According to this model, smoking induces protein citrullination 
in the lung, which predisposes to the production of ACPA and, subsequently, of RA11. This model has been sup-
ported by other findings, including the demonstration of increased PAD2 expression in bronchoalveolar lavage 
(BAL) of smokers12,13. However, not all the findings have been consistent. In particular, no correlation between 
smoking and protein citrullination12,14,15 or between smoking and PAD215 have been observed in the lung tissue 
specimens. Moreover, the production of ACPA in the lung and the presence of lung abnormalities in early RA 
were directly associated with ACPA+ RA without detectable association with smoking in the available studies16–19. 
Also, van Wesemael et al. reported that smoking was associated with the concurrent presence of RF, ACPA and 
ACarPA, rather than with ACPA in three patient cohorts20. The novelty and repercussion of these latter results ask 
for validation through independent replication.
Here, we have replicated and extended the findings of van Wesemael et al. in an independent set of six patient 
cohorts (n = 2253). Our results confirmed the predominant association of smoking with the concurrent presence 
of the three RA autoantibodies. Also, thanks to the large power afforded by the combined analysis (n = 4491), we 
discovered that smoking was exclusively associated with RF positivity in the patients without three concordant 
positive autoantibodies (RF+1+2). In contrast, we did not find significant associations of smoking with the specific 
presence of ACPA or ACarPA. These results indicate that smoking promotes pathways leading to the concurrent 
presence of the three RA autoantibodies and, in its defect, to the production of RF.
Material and Methods
patients and samples. Patients from five Spanish (IDIPAZ, PEARL, IDIS, IdISSC, and IDIVAL) and one 
Italian (Rome) RA cohorts were considered as replication sets (n = 2253 with complete data). The Spanish data 
were directly available to us, whereas the information corresponding to the Italian patients was extracted from 
a publication21. Two of the replication collections were early arthritis (EA) prospective clinics (IDIPAZ and 
PEARL), whereas the remaining four replication cohorts (IDIS, IdISSC, IDIVAL and Rome) were from estab-
lished RA patients. Entry criteria for IDIPAZ22 and PEARL23 were: 2 or more swollen joints for less than a year 
and absence of previous treatment with Disease Modifying Anti-Rheumatic Drugs (DMARD). In addition, 
the patients with RA according to the 1987 ACR criteria24 at 2 years of follow-up and with serum samples and 
smoking information in the baseline visit (IDIPAZ, n = 243; and PEARL, n = 264) were selected. The established 
Spanish RA patients (according to 1987 ACR criteria, with serum samples and information on smoking) were 
from IDIS25, n = 470, IdISSC26, n = 508, and IDIVAL27, n = 459. In turn, the Italian patients (n = 309) were clas-
sified according to the 2010 ACR criteria21. Smoking information was obtained as never smoker, past smoker or 
current smoker in response to the written questionnaire given to the patients at recruitment, either at the first 
visit (all patients in IDIPAZ and PEARL) or at any time (in the remaining cohorts). No information on smoking 
intensity was available from most patients. All the patients included in this study granted their written informed 
consent. The study was designed and conducted according to the Declaration of Helsinki, the Belmont Report 
and the Spanish Law 14/2007 of Biomedical Research. This included the approval of the Hospital Clínico San 
Carlos Ethics Committee, the Cantabria Ethics Committee, the EAC by the La Paz University Hospital Ethics 
Committee, the Ethics Committee for Clinical Research of Hospital Universitario La Princesa (Ref. PI-518), 
and the approval of the study by the Autonomous Research Ethics Committee of Galicia (Ref. 2014/387 and 
2017/514).
For meta-analysis, data from the three patient collections (NOAR, EAC Leiden and BARFOT) included in the 
van Wesemael study (n = 2238 with complete information) were retrieved20.
Anti-carp antibodies and other RA autoantibodies. Anti-CarP IgG antibodies were assessed by 
ELISA as previously described25,28. IgM-RF was determined by rate nephelometry, whereas ACPA were deter-
mined by ELISA. The ACPA were tested as anti-CCP2 with the EDIA enzyme-linked immunosorbent assay kit 
in all the IDIS and IDIVAL patients and with the Immunoscan RA in all the IDIPAZ and IdISSC patients (both 
assays from Euro Diagnostica, Malmö, Sweden). The patients of PEARL were tested with Immunoscan RA until 
October 2010. Afterward, they were assayed with the QUANTA Lite CCP3 IgG and IgA assay (Inova Diagnostics, 
San Diego, CA).
Statistical analysis. Results from the different patient cohorts, and from previously reported cohorts20,21, 
were combined by meta-analysis with the R package meta29. Subgroup meta-analysis comparing EAC and prev-
alent RA cohorts was done with Review Manager Version 5.330. Smoking habit was considered as ever or never 
smoker status. In most analyses, the RF−ACPA−ACarPA− triple negative patients (0 Ab) were used as the refer-
ence. Alternative meta-analyses compared other patient subgroups, which are indicated in the text with a com-
bination of the antibody abbreviation (RF, ACPA or ACarPA), the plus and minus superscripts for presence/
absence, and the number of antibodies considered (from 0 to 3) as subscripts. In this way, the patients bearing 
only RF are coded as RF+1, those bearing RF and a second antibody as RF+2. See Supplementary Table S1 for the 
remaining codes. Heterogeneity between cohorts was assessed with the inconsistency parameter I2. By default, 
the fixed effects model was applied for meta-analysis, weighting the contribution of each cohort with the inverse 
variance method. The random effects model according to DerSimonian and Laird was preferred when hetero-
geneity was notable (I2 > 50) and reported as ORre and pre. P values lower than 0.05 were considered statistically 
significant.
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Additionally, we used exploratory analysis on the pooled data across the cohorts for interpretation of the 
findings. It included graphic representation and classification trees. For the former, we employed a double-decker 
plot31. The classification trees, in turn, were done with the General Classification and Regression Trees module of 
Statistica (v7.0, StatSoft, Tulsa, OK) that produces an exhaustive and recursive search of the best classification. We 
considered nine dichotomous variables to classify the patients according to smoking. The variables represented 
the presence or absence of the antibodies, their combinations and number: RF, ACPA, ACarPA, RF&ACPA, 
RF&ACarPA, ACPA&ACarPA, one antibody, two antibodies, and three antibodies. The priors were considered 
proportional to the smoking class sizes, the misclassification costs were taken to be equal for every class, the splits 
were selected based in the Gini index of node impurity, and no stops were imposed. This procedure searches the 
minimum number of univariate splits to produce the tree with less misclassified patients without being limited by 
the high dependence between the classification variables.
Results
Replication of the association of smoking with concurrent autoantibodies. The six newly 
obtained cohorts of RA patients included 2253 patients with complete data (Table 1). Two of the cohorts were 
prospective EAC (n = 507), the remaining included patients with established RA (n = 1746). About half (43.6–
55.1%) of the patients were ever smokers, except in one of the cohorts where the frequency of smokers was 
notably lower (20.4%). This circumstance is characteristic of the population attending the recruiting hospital, as 
previously noted32. The other critical characteristic for this study, the presence of autoantibodies, varied between 
the cohorts within the commonly observed range: mean percentages of RF+ = 61.7%, ACPA+ = 57.7%, and 
ACarPA+ = 34.4%. The patients were divided into four subgroups by the number of antibodies they presented. 
These subgroups were of comparable size except for the patients with one antibody that were the less abundant: 
26.6, 18.8, 28.8 and 25.8% for the groups with 0, 1, 2 and 3 antibodies, respectively.
We assessed the relationship of smoking with the patients grouped according to the number of antibodies 
they presented (Table 2). Only the patients positive for the three autoantibodies were significantly associated with 
smoking (3 Ab vs. 0 Ab: OR = 1.99, p = 2.5 ×10−8). In stark contrast with this very significant result, the patients 
with one or two autoantibodies were not significantly different from the patients without antibodies (Table 2). In 
addition, the association of smoking with the concurrent presence of the three antibodies was significant not only 
relative to the patients without antibodies (Table 2), but also relative to the patients with one antibody (3 Ab vs. 
1 Ab:OR = 1.68, 95% CI = 1.32–2.13, p = 2.2 ×10−5, I2 = 0%) and with two antibodies (3 Ab vs. 2 Ab: OR = 1.61, 
95% CI = 1.27–2.04, p = 8.1 ×10–5, I2 = 0%).
combined meta-analysis of the available data. We combined the 6 replication cohorts with the 
3 cohorts form van Wesemael et al.20 to a total of 4491 patients with RA. The summary data showed that the 
association with the concurrent presence of the three antibodies was highly significant (Fig. 1C, 3 Ab vs. 0 Ab: 
OR = 2.00, p = 4.4 ×10−16, I2 = 17%), and significantly stronger than the observed with the patients carrying two 
antibodies when directly compared (3 Ab vs. 2 Ab: OR = 1.54, 95% CI 1.29–1.84, p = 1.4 ×10−6, I2 = 12%). Even 
so, the patients with two concordant positive antibodies were associated with smoking (Fig. 2B, 2 Ab vs. 0 Ab: 
OR = 1.26, p = 0.009, I2 = 41%). In contrast, the patients carrying only one antibody were not significantly associ-
ated with smoking (Fig. 2A, 1 Ab vs. 0 Ab: ORre = 1.12, pre = 0.4, I2 = 56%). These associations were not different 
in the EAC and the prevalent RA cohorts (Supplementary Table S2).
Association of smoking with the presence of Rf in the patients with one or two positive anti-
bodies. The patients carrying RF accounted for the smoking associations in the patients without the concur-
rent presence of the three antibodies. First, the specific RF association was found in RA patients with only one 
positive antibody (1 Ab) (Supplementary Table S3). In them, the patients carrying RF (RF+1) were associated 
with smoking (RF+1 vs. 0 Ab: OR = 1.28; 95% CI = 1.03–1.61; p = 0.03), whereas the RA patients carrying other 
Cohort
New cohorts van Wesemael et al.
IDIPAZa PEARLa IDIS IdISSC IDIVAL Romeb NOARa
EAC 
Leidena BARFOTa
Complete data, n 243 264 470 508 459 309 674 769 795
Ever smoker, n (%) 117 (48.1) 115 (43.6) 96 (20.4) 232 (45.7) 253 (55.1) 167 (54) 432 (63.7) 415 (54) 471 (59.2)
RF positive, n (%) 168 (69.1) 175 (66.3) 281 (59.8) 329 (64.8) 235 (51.2) 202 (65.4) 277 (40.9) 442 (57.5) 448 (56.4)
ACPA positive, n (%) 170 (70) 163 (61.7) 300 (63.8) 251 (49.4) 225 (49) 190 (61.5) 247 (36.4) 404 (52.5) 456 (57.4)
ACarPA positive, n (%) 109 (44.9) 100 (37.9) 141 (30) 158 (31.1) 149 (32.5) 117 (37.9) 182 (26.8) 349 (45.4) 279 (35.1)
Number of autoAb.
0 54 (22.2) 59 (22.3) 111 (23.6) 141 (27.8) 173 (37.7) 62 (20.1) 292 (43.1) 242 (31.5) 263 (33.1)
1 21 (8.6) 45 (17) 95 (20.2) 118 (23.2) 78 (17) 67 (21.7) 167 (24.6) 129 (16.8) 110 (13.8)
2 78 (32.1) 87 (33) 165 (35.1) 127 (25) 93 (20.3) 98 (31.7) 108 (15.9) 128 (16.6) 193 (24.3)
3 90 (37) 73 (27.7) 99 (21.1) 122 (24) 115 (25.1) 82 (26.5) 107 (15.8) 270 (35.1) 229 (28.8)
Table 1. Main characteristics of the patients with RA. Analysis of the six new cohorts (n = 2253) that were 
studied here for the first time and of the three cohorts (n = 2238) from a previous study20. aEarly arthritis 
patients. bData extracted from Pecani et al.21.
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positive antibodies (RF−1) were indistinguishable from the triple negative patients (RF−1 vs. 0 Ab: ORre = 1.01; 
95% CI = 0.65–1.56; pre = 0.97). In addition, smoking was also associated with the presence of RF in the RA 
patients carrying two positive antibodies (2 Ab) (Supplementary Table S4). In effect, the patients in whom one of 
the two positive antibodies was RF (RF+2) were significantly associated with smoking (RF+2 vs. 0 Ab: OR = 1.30; 
95% CI = 1.09–1.55; p = 0.004), whereas the other patients carrying two antibodies (RF−2) were undiscernible 
from the triple negative patients (RF−2 vs. 0 Ab: OR = 0.95; 95% CI = 0.64–1.39; p = 0.78). Similar analyses cen-
tered on the presence of ACPA or ACarPA did not show any significant association.
A notable finding of the preceding analysis was the very similar association (OR = 1.28 and 1.30) of smoking 
with patients carrying RF in the patients with only one positive antibody (RF+1) and with two positive antibodies 
(RF+2). This equivalence was confirmed when the associations of smoking with these two subgroups of patients 
were directly compared (RF+2 vs. RF+1: p = 0.9). As a consequence, the RF+ patients carrying one or two positive 
antibodies were grouped (RF+1+2). As expected, smoking was associated with this unique RF+ subgroup (Fig. 2A, 
RF+1+2 vs. 0 Ab: p = 0.001, I2 = 45%). An association that was slightly reinforced when all the RF− patients were 
used as reference (Fig. 2B, RF+1+2 vs. RF−0+1+2: p = 0.0002, I2 = 0%). It should be remarked that the patients with-
out RF in this latter analysis (RF−0+1+2) included patients positive for ACPA or ACarPA or both these antibodies. 
The previous associations were not significantly different in the EAC and the cohorts including prevalent RA 
patients (Supplementary Table S5).
Global exploratory analysis. We used two exploratory techniques to check if a global analysis of all patient 
subgroups together was consistent with the sequential analyses in the preceding paragraphs without generating 
redundant statistical tests.
First, the relative frequencies of ever smokers and never smokers in each of the autoantibody-defined strata 
were displayed with a double-decker plot. Consistently with the results obtained in the sequential analyses, the 
smokers were enriched in the RF+ patients relative to the corresponding RF− patients in all the strata (Fig. 3).
The second exploratory analysis consisted of an exhaustive search of the best classification tree discriminat-
ing ever smokers from never smokers based on the antibodies and their combinations (Fig. 4). The first split of 





Non-smoker, nb 40 7 38 41
Smoker, n 14 14 40 49
PEARL
Non-smoker, n 37 28 51 33
Smoker, n 22 17 36 40
IdISSC
Non-smoker, n 90 60 75 51
Smoker, n 51 58 52 71
IDIS
Non-smoker, n 83 81 138 72
Smoker, n 28 14 27 27
IDIVAL
Non-smoker, n 88 39 41 38
Smoker, n 85 39 52 77
Rome
Non-smoker, n 31 34 45 32
Smoker, n 31 33 53 50
Summary statistics
OR 1 (ref.) 1.19 1.19 1.99
95% CI — 0.91–1.55 0.94–1.52 1.56–2.54
p — 0.21 0.15 2.48 × 10−08
I2, % — 68.9 56.9 25.9
ORre 1 (ref.) 1.22 1.22 1.99
95% CIre — 0.74–2.01 0.84–1.77 1.49–2.64
pre — 0.43 0.30 2.47 × 10−06
Table 2. Association of smoking with seropositive patients with different numbers of autoantibodies in the new 
patient cohortsa. aThe table presents the number of patients in each category in the upper part and the summary 
statistics obtained with meta-analysis in the lower part. The triple negative patients were used as reference (ref.) 
for the patients with 1, 2 or 3 antibodies. bn = number of subjects; OR = odds ratio; CI = confidence interval; 
I2 = inconsistence; the re subscript indicates the random effects model.
5Scientific RepoRtS |         (2020) 10:3355  | https://doi.org/10.1038/s41598-020-60305-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
seropositivity (3 Ab) contained 61% of smokers, whereas the remaining patients only 48% of smokers. No other 
antibody or combination contributed to the classification of the concordant patients. In contrast, two more divi-
sions were observed in the non-concordant patients. The second split was on the presence of RF. The RF+ group 
(RF+1+2) contained more smokers than the RF− stratum (RF−0+1+2). The third split was unanticipated and com-
plex. It divided the RF+ patients into a smoker-enriched subgroup in whom RF was the only present antibody 
(RF+1), and a smoker-depleted subgroup in which RF was present concurrently with other antibodies (RF+2). 
This latter division reinforced the exclusivity for RF of the smoking association in the patients with one or two 
antibodies.
Discussion
Our main findings have been the predominant association of smoking with the concordant presence of the three 
RA antibodies, and the exclusive association with the presence of RF in the seropositive patients with one or two 
antibodies (RF+1+2). In addition, there was no significant association of smoking with the presence of ACPA 
or ACarPA. These findings have represented a significant advance. In van Wesemael et al.20, the association of 
Figure 1. Smoking association with seropositivity for different numbers of autoantibodies in the combined 
meta-analysis. Forest plots showing the fixed-effect meta-analysis involving the RA patients that were positive 
for (A) one, (B) two, and (C) three autoantibodies. The patients without antibodies (0 Ab) were taken as 
reference. The OR corresponding to each cohort (Study) and its 95%-CI are provided and shown by a vertical 
tick and the length of a horizontal line, respectively. The area of the square around the tick is proportional to 
the size of the study. Summary OR and 95% CI are given in bold and represented as a vertical dashed line and a 
diamond, respectively. The OR scale is logarithmic.
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Figure 2. Association of smoking with the presence of RF in the RA patients carrying one or two antibodies. 
Forest plots showing the comparison of: (A) RF+ patients that were positive for one or two antibodies (RF+1+2) 
with the patients without antibodies (0); and (B) the comparison of RF+ patients that were positive for one or 
two antibodies (RF+1+2) with all the RF− patients (RF−0+1+2). No cohort-specific information was available for 
the three cohorts in van Wesemael et al. Plots follow Fig. 1 conventions.
Figure 3. Smoking frequency in the patients stratified by the presence of the three autoantibodies. The double-
decker plot divides the patients in rectangles proportional to the frequency in each subgroup. The width is 
proportional to the size of the antibody-defined patient subgroups, whereas the height of the red rectangles is 
proportional to the ever smokers within the antibody subgroups.
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smoking with RA could represent a gradual increase in the strength of association with the number of antibodies. 
The evidence presented here excludes this putative mechanism by the demonstration of the exclusive association 
of smoking with RF independently of the presence or absence of other antibodies in the patients carrying one or 
two antibodies, and by the clear distinction between the patients with three antibodies as a separate classification 
to other seropositive patients. This fundamental insight determines the nature of the models aiming to explain the 
effect of smoking on RA susceptibility. In addition, our analysis has made more understandable the relationship 
between smoking and the antibodies thanks to the exploratory techniques. They also showed that the results of 
the statistical tests were faithful to the data.
The originality of our findings is reflected in the absence of any other study analyzing the association of smok-
ing with combinations of the three antibodies included here and in van Wesemael et al.20. Therefore, we consid-
ered the studies assessing the combination of RF and ACPA as antecedents. We have found only reports from four 
large cohorts20,33–35, one of them included in van Wesemael et al. but different from the RA cohorts included in 
our meta-analysis. The four cohorts were large, with ≈9500 healthy Japanese subjects20, ≈2000 UK RA patients33, 
≈1500 USA RA patients34, and ≈3600 Swedish RA patients35. The three first have shown a significant association 
of smoking only with the concurrent presence of the two antibodies, not with any of them in isolation. The forth 
by Hedstrom et al. showed a stronger association with the concurrent presence of RF and ACPA, followed by RF 
and less significantly by ACPA (more on the results of this study below). These results and those of another study 
with two smaller UK RA collections36 are fully compatible with our findings. In addition, the bibliographic search 
brought to our attention another important fact. None of the studies that support the pathogenic model linking 
smoking with RA through the production of ACPA has accounted for the association of smoking with the con-
current presence of ACPA and RF10,11,37–39 until very recently35.
We do not know the mechanism behind the predominant association of smoking with the concurrent pres-
ence of RA autoantibodies. However, it is well-known that the status of the RA autoantibodies is much more 
concordant than at random25,28,40. This circumstance reveals the existence of pathogenic mechanisms that are 
shared by the various antibodies. Some of these mechanisms contribute to epitope spreading, which characterizes 
the progression of T and B cell responses in autoimmune diseases including the preclinical phase of RA3–5,41,42. 
In effect, the earliest seropositive samples from patients that will develop RA years later often recognize a single 
epitope, whereas samples taken near the clinical onset recognize multiple epitopes3–5. Therefore, smoking could 
promote concordant seropositivity by broadening and accelerating epitope spreading.
The known factors affecting epitope spreading include the availability of epitope-specific lymphocytes, 
reflecting incompetent tolerance, and favorable T - B cell interactions and antigen presentation41,42. The latter 
interactions could be boosted by bystander activation, tissue damage and inflammation. Therefore, smoking 
could promote epitope spreading through these multiple mechanisms. This is possible because the triggering of 
inflammation and tissue damage, the recruiting and activation of neutrophils, monocytes, and macrophages, and 
abnormalities in NK, dendritic cells, B cells and many subtypes of T lymphocytes are some of the many effects of 
Figure 4. Classification tree of the patients by the presence of antibodies according to smoking. Each node 
shows its number (upper left corner), the percentage of ever smokers (upper right corner), and an histogram 
representing the frequency of ever smokers (continuous line) and never smokers (dotted line). Decision nodes 
are in blue whereas terminal nodes are in red. The splitting conditions are displayed below the node with 
indication of the value determining each side of the split and the number of subjects sent to the child node.
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smoking on the immune responses43,44. The overall balance of this range of actions is an increased predisposition 
to autoimmunity and the production of autoantibodies43,44. Specifically, smoking has been associated with the 
production of anti-dsDNA in SLE45, anti-Jo1 in inflammatory myopathies46 and of RF and other autoantibodies 
in smokers without any autoimmune disease20,47–50.
The sharing of immunological mechanisms between the autoantibodies is also the most likely explanation for 
the correlation between their antibody titers, a correlation that we have also observed in our analyses25,51–53. These 
correlations have been observed independently of the disease stage and, most significantly, to be maintained as 
parallel titer decreases in response to treatment revealing that they respond similarly to the control of inflamma-
tion51–53. These correlations lack any specific direction and extend to the thresholds for establishing the positive/
negative status (Supplementary Table S6). Therefore, they are unlikely to denote any hierarchy of precedence or 
causality between the antibodies. Just recently, some of these examples of shared and overlapping immunological 
mechanisms have been characterized as the convergent pathways model of RA pathogenesis54.
The association of smoking with RF in the patients with one of two antibodies suggests that RF could precede 
other autoantibodies in the smokers that will become RA patients. However, we lack support for this interpre-
tation given the cross-sectional nature of our sample collections. In addition, the studies of preclinical RA sam-
ples have been discordant in the order of antibody appearance: IgA RF and IgM RF were the first antibodies in 
a Swedish cohort55, whereas ACPA4 and ACarPA56 preceded IgM RF in a Dutch cohort, and again IgG ACPA 
preceded RF (no ACarPA analysis included) in American military57. Similarly, the presence of RF in smokers 
without RA that has been known for more than two decades49,50, cannot be taken as evidence of RF preceding the 
other autoantibodies because recent studies have found also an increased presence of ACPA in smokers without 
RA20,58. In consequence, we will need to wait for new studies to solve this question.
Independently of the order of appearance, we need an explanation for the specific association of smoking 
with RF. A couple of possible mechanisms have already been proposed. One of them was originally developed 
to explain the production of autoantibodies in smokers without autoimmune diseases48. It starts by the induc-
tion of heat-shock protein 70 (Hsp70) expression and of antibodies against Hsp70 by smoking. In the next step, 
the production of RF is triggered by the two signals given by the Hsp70 immune complexes (IC): through the 
BCR recognizing the anti-Hsp70 IgG, and through CD91 binding Hsp70. These details were delineated in mouse 
experiments48, but their reproducibility in RA patients is unclear. A second hypothesis proposes that smoking 
leads to increased lung production of IgG, which would be recognized by RF in its native form and by ACPA 
and ACarPA as the citrullinated and carbamylated modified IgGH fragment, respectively59. This hypothesis 
has the appeal of the simplicity of considering a single protein as the link between the different RA antibodies. 
Accordingly, it has been characterized as the common antigen model54. However, only RF is known to recognize 
the IgGH fragment, in the form of IgGH/HLA class II complexes60, whereas the binding of the modified IgGH 
fragment by ACPA or ACarPA has not been reported. The two hypotheses could become the starting point for 
future experiments.
The association of smoking with RF positive RA was known before the association with the ACPA positive 
patients6,7, however, the latter displaced RF from the focus of attention1,2. Probably, the peculiar nature of RF 
has some role in this displacement. In effect, RF can be described as an antibody against IC with a role in the 
development of the early antibody repertoire that in the adult can be induced in the course of sustained immu-
nological responses that include other diseases besides RA61–63. However, the nature of the RF in patients with 
RA and non-RA subjects have significant differences. In RA, the RF production is sustained and reach higher 
titers; also, the range of Ig V genes that are used is broader, and the response shows signs of maturation as isotype 
switch and mutations changing the sequence of the CDRs, characteristics that are absent or restricted in the 
RF of healthy subjects62,63. It is understood that ACPA and citrullinated proteins, or ACarPA and carbamylated 
proteins, are the IC recognized in RA, but other antibodies are possible as the anti-Hsp70 antibodies (in relation 
to smoking) and microbial antigens (including those from viruses and the mucosal microbiota). These diverse 
IC could act as disease triggers48,61. Once RF binds to the IC, the IC become larger and capable of more efficient 
immune stimulation. A model of RA in which two waves of IC formation, without RF and with RF, followed by 
complement activation and the production of inflammatory and chemotactic mediators has been proposed61. It is 
also possible that the RF-specific B cells have a critical role in the early phases of the autoimmune response before 
high titers of RF have been produced63. In effect, the RF specific B cells are abundant in healthy subjects and the 
only B cells capable of efficient presentation to T cells of the antigens trapped in IC64. These various roles of RF 
and the RF-specific B cells could contribute to epitope spreading and the concordance and correlation between 
the RA autoantibodies.
The fact that our meta-analysis did not detect any specific association of smoking with the presence of ACPA 
in the patients without RF (OR = 0.95, 95% CI = 0.78–1.20) does not exclude association with a subset of the 
ACPA+ patients. Examples of such subsets could be the patients with shared epitope HLA alleles or patients with 
heavy and current smoking. Concerning the HLA, the presence of the shared epitope is specifically associated 
with the presence of ACPA and there are arguments to think it could potentiate the smoking association. The most 
clear argument comes from a recent study by Hedstrom et al. showing association with ACPA+/RF− 35, whereas 
previous studies failed to stratify by the two antibodies or did not find a significant association10,11,33,34,36–39. The 
other example is supported by the same recent study, which showed differential association of heavy smokers 
and light smokers with RA. A difference that was more marked in the ACPA+/RF+ patients, followed by the 
ACPA−/RF+ patients and finally the ACPA+/RF− patients35. This differential association is in agreement with our 
results placing the concordant seropositivity at the top and RF afterwards. However, the ACPA+/RF− patients in 
Hedstrom et al. were significantly associated with smoking and they were not in our meta-analysis.
Our study lacks healthy controls and therefore, we were restricted to comparisons between patient sub-
sets. However, this is a minor limitation because the association of smoking with seropositive RA patients is 
well-established6,7. In addition, the study lacks information on smoking intensity and HLA alleles. These two 
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types of information could have provided additional insight into the relationship between smoking and the 
different autoantibodies. In any case, a whole analysis of the potential interactions between smoking and the 
HLA in the three autoantibodies is not yet possible because only the HLA alleles associated with ACPA are 
well-defined65. The other antibodies, ACarPA and RF, could be specifically associated with HLA-DRB1 alleles 
that are not included in the shared epitope, but that have not been yet completely defined66–68. Finally, we should 
signal that the classification tree in Fig. 4 is not appropriate to separate smokers and non-smokers. This algorithm 
was only intended as a tool to explore the relationships between smoking and the antibodies present in the data.
In summary, we can conclude that smoking is predominantly and reproducibly associated with the triple, RF, 
ACPA, and ACarPA, concordant seropositive RA. A result that highlights the need to consider the mechanisms 
leading to concurrent seropositivity. In the patients that are not concordant for the three antibodies, smoking was 
exclusively associated with RF positivity in our meta-analysis. This latter association is weaker than the associa-
tion with the triple concordant patients and its exclusivity needs to be replicated, ideally in studies counting with 
detailed information on smoking intensity. These results call for a pathogenic model that incorporates the pre-
dominant association with multiple antibodies, which could be explained by accelerated and broadened epitope 
spreading reflecting some of the actions of smoking on the immune system. In addition, an explanation for the 
particular association of smoking with the production of RF should be sought.
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